fourth-quart top-lin bottom-lin miss guidanc
thursday februari market open report fourth quarter
full year financi result exhibit provid jakafi guidanc
total revenu quarter million estim million
consensu million top-lin beat due recognit million
sale mileston relat jakavi europ quarter jakafi net product revenu
unit state million line estim million
slightli consensu million iclusig revenu record
million estim million consensu million
quarter record million olumi royalti sale bottom
line non-gaap net incom quarter million estim
million consensu million non-gaap ep quarter
estim consensu full-year non-gaap ep
estim consensu bottom-lin miss due lower-
than-expect total product revenu slightli higher oper expens anticip
end quarter billion cash cash equival complet varianc
analysi expect consensu actual result summar exhibit
compani guid jakafi guidanc billion billion midpoint
slightli consensu estim billion
return equiti ttm
base wilmington delawar major oncology-focus biotechnolog compani
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
recent upgrad share outperform detail pleas refer note publish januari
pipelin final come epacadostat shadow prospect also strong upgrad perform
continu believ execut commerci front balanc drive near-term
profit growth realiz long-term growth deep pipelin lead share out-performance
regulatori catalyst includ potenti approv jakafi steroid-refractori graft-versus-host diseas gvhd
add jakafi growth nda submiss pemigatinib refractori cholangiocarcinoma compani announc
today grant breakthrough therapi design fda well nda submiss capmatinib non
small-cel lung cancer nsclc partner novarti nv entitl mileston
royalti sale pivot data catalyst includ jakafi itacitinib variou gvhd phase studi look
occupi frontlin steroid-refractori set gvhd two agent potenti approv
pemigatinib pivot data bladder cancer near year-end exhibit compani also continu pursu strategi
extend jakafi life-cycle explor combin in-hous agent pim inhibitor itacitinib inhibitor
parsaclisib inhibitor success combin improv treatment success serv build
base busi myeloprolif neoplasm mpn beyond patent expir jakafi
manag also note cash reserv increas compani could look diversifi revenu within next two
year ad late-stag asset good qualiti fit compani portfolio
manag issu non- guidanc continu reflect consist top-lin growth led
jakafi continu expens manag balanc execut current clinic studi upcom
commerci launch invest pipelin in-hous effort collabor
program made follow chang model reflect updat
manag issu jakafi sale guidanc billion billion repres increas
midpoint compani also reiter long-term guidanc billion billion
unit state lower estim slightli billion billion previous
within guidanc maintain above-guid street-high estim billion peak
jakafi sale manag comment end fourth quarter inventori back within normal
rang annual jakafi product sale believ pattern continu
augment beyond follow potenti label expans gvhd essenti thrombocythemia
peak estim jakafi penetr elig mf popul elig pv
popul exhibit jakafi remain approv therapi second-lin set indic
potenti competitor near medium term note januari celgen celg
outperform obtain global right fedratinib inhibitor registr mf clinic develop
pv part acquisit impact biomedicin howev view fedratinib threat jakafi
believ ultim use salvag jakafi failur compani also continu explor combin
jakafi extend domin mf pv in-hous agent includ pim inhibitor itacitinib
inhibitor parsaclisib inhibitor attempt maintain domin indic
compani guid sg million million repres increas
midpoint increas sg estim million million near
midpoint guidanc
 cog expect come within rang billion billion
million million respect maintain estim billion slightli decreas
cog estim million million previous fit guidanc
base chang estim non-gaap ep previou estim
differ attribut slightli lower revenu higher oper expens match guidanc
referenc
continu execut develop extens pipelin clinic asset includ five novel
candid potenti enter market next five year well strategi continu growth
base busi follow failur studi epacadostat earlier year focu shift toward
compani clinic preclin pipelin program coupl continu commerci growth extens
jakafi franchis exhibit
project blockbust jakafi maintain doubl digit year-over-year growth year come fda
recent extend review period snda jakafi steroid-refractori acut gvhd current
model attribut million peak sale new pdufa date set may note
extend review period like due fda lack experi evalu gvhd treatment compani
remain confid strong efficaci safeti data deliv fda expect regulatori
approv soon compani also note extens impact evalu on-going gvhd studi
includ expect data second half
jakafi also evalu steroid-refractori chronic gvhd essenti thrombocytopenia et
compani continu explor combin in-hous agent includ pim inhibitor itacitinib
inhibitor parsaclisib inhibitor life cycl manag
look expand footprint beyond jakafi steroid-refractori gvhd gravita program
select inhibitor itacitinib cover unmet need steroid-nav prophylact gvhd
space itacitinib pace potenti approv extend beyond jakafi breadth treatment
steroid-refractori acut chronic gvhd compani use itacitinib target steroid-nav acut chronic
gvhd first phase trial itacitinib seek enrol patient steroid-nav
acut gvhd random receiv itacitinib placebo combin steroid primari endpoint orr
overal respons rate day top-lin data expect success would lead itacitinib first
global regulatori submiss second phase studi steroid-nav chronic gvhd initi
januari success manag project itacitinib see approv second indic
time frame project potenti launch itacitinib unit state europ
respect ascrib probabl success exhibit
februari partner announc top-lin result two five phase studi olumi
treatment moder sever atop dermat olumi jak inhibitor partner
approv fda first indic treatment moder sever ra june olumi
second indic moder sever atop dermat patient refractori topic steroid compani issu
top-lin press releas state statist signific proport patient treat olumi met
week primari endpoint investig global assess iga score clear almost clear first two
five phase studi note mg dose olumi approv ra due imbal
thrombosi event higher dose howev safeti issu report mg dose ad patient
believ like ra patient higher risk seriou infect cardiovascular event
anticip report top-lin data three on-going studi later year expect compani
file nda second half follow potenti approv post-top moder sever atop dermat
unit state europ respect ascrib probabl commerci
olumi atop dermat exhibit
interim result trial pois pemigatinib first-in-class select fgfr inhibitor
patient advanced/ metastat surgic unresect cholangiocarcinoma nda submiss
expect late catalyst indic anticip follow european societi medic
oncolog esmo octob munich compani present interim result two on-going studi
inhibitor pemigatinib treatment cholangiocarcinoma bladder cancer uc
given data present believ pemigatinib could best-in-class second line
cholangiocarcinoma transloc nda file expect third quarter compani
announc today pemigatinib grant breakthrough therapi design fda indic
compani also recent began recruit patient pivot trial pemigatinib first-lin treatment
cholangiocarcinoma also believ pemigatinib could like player urotheli carcinoma uc bladder
cancer fusion continu dose pemigatinib set improv potenc see right
potenti snda pemigatinib uc expect cholangiocarcinoma pemigatinib produc orr
month second-lin cholangiocarcinoma transloc cohort patient
closest competitor qed privat infigratinib produc orr month
set date slightli shorter follow metastat surgic unresect uc
patient fusion pemigatinib treatment result orr intermitt dose
comparison johnson johnson erdafitinib demonstr impress orr cr
among patient set phase ii studi note johnson johnson abl
improv orr switch intermitt continu dose follow suit
recruit anoth cohort patient continu dose suspect efficaci would improv
well also expect begin tumor agnost pemigatinib pivot trial note variou tumor
fgfr mutat transloc repres addit patient could benefit
beyond candid believ select number earlier-stag candid start move
forefront could add valu near medium term exhibit addit program includ topic jakafi
treatment vitiligo inhibitor relapsed/refractori r/r set follicular lymphoma fl margin zone
lymphoma mzl mantl cell lymphoma mcl oral inhibitor first bi-specif antibodi meru
collabor hold high promis view
maintain outperform rate fair valu share exhibit probability-adjust net
present valu npv model assign per share jakafi per share iclusig per share olumi
pemigatinib itacitinib also assign per share capmatinib royalti novarti ad per share
net cash year-end arriv fair valu assess share
upcom catalyst includ approv jakafi steroid-refractori acut gvhd nda
submiss pemigatinib cholangiocarcinoma phase data jakafi steroid-refractori acut chronic gvhd
phase ii data ruxolitinib cream vitiligo phase data itacitinib steroid-nav acut gvhd
proof concept data margin zone lymphoma mzl mantl cell lymphoma mcl follicular
lymphoma fl
risk outperform rate includ clinic risk pipelin unforeseen competit
jakafi safeti risk olumi
incom iclusig eu epacadostat revenues- contract total product sg chang fair valu acquisition-rel conting expenses- total oper oper interest incom interest debt exchang expens senior note unreal loss long term invest loss repurchase/redempt conv senior subordin total incom pre-tax comprehens gain/ loss accret redempt valu redeem conv prefer stock- provis incom net reconciliationmileston revenu new exist up-front consider mileston relat non-cash stock comp equiti asset impair in-process chang fair valu conting amort acquir product chang fair valu equiti non-cash interest exp relat conv expens relat senior note tax effect non-gaap total non- non- net non- ep ep weight averag share outstand weight averag share outstand sourc william blair estim compani corporationincom statement dollar thousand except per blair estimateswillam blair estimatesactualactualwb estimate actual vs estimate con estactu vs consactu q/q growthcurrentpreviouscurr vs previousy/i growthcurrentpreviouscurr vs previousy/i growthin thousand except per share datarevenuesjakafi net product expens oper net ep william blair estim factset compani reportsexhibit corporationvari analysi william blair
compani report compani reportsexhibit newsflow develop projectssettingpreval incid probabl successlaunch dateindicationwb estimate current market sharewb modelpeak shareprice/yeartreat durationpeak salespeak global high-risk myelofibrosi includ primari myelofibrosi post-polycythemia vera myelofibrosi post-essenti thrombocythemia high risk polycythemia vera intoler inadequ respons acut chronic high risk hu intoler essenti thrombocythemia intoler inadequ respons hydroxyurea harbor william blair estim compani reportsexhibit corporationjakafi assumpt william blair
time indic initi submiss seek market approv indic compani reportsexhibit corporationpotenti new product indic launch candidateindicationpopul addressedu incid target populationprob successlaunch datewb modelpeak shareprice/yeartreat durationpeak salespeak global salesvaluationolumiantatop dermatitismoder sever atop dermat patient gvhdsteroid-na acut chronic month month diagnos metastat unresect patient cancernewli diagnos metastat unresect patient mutat advanc non-smal cell lung william blair estim compani reportss william blair estim compani reportsexhibit corporationnon-jakafi assumpt william blair
drugind statusnotessteroid-refractori acut gvhdsnda accept prioriti review base phase review period extend three monthssteroid-refractori chronic gvhdphase thrombocythemiaphas ii reset refractori myelofibrosisphas ii combin parsaclisib pim itacitinib acut gvhdphase acut gvhdphase cell lung cancerphas i/ii combin osimertinib egfr follicular lymphomaphas ii zone lymphomaphas ii cell lymphomaphas ii cancerphas ii ii phase mpnphase ii tumor driver activ fgf/fgfrpivot program pim hematolog malignanciesphas i/ii dose-escalationdevelop combin jak myeloid leukemia small cell lung cancerphas i/ii dose-escalationepigenet mechan target cell carcinomaphas i/ii greater select initi develop expect focu hepatocellular carcinomaepacadostat cancerphas ii combin keytruda msi-high endometri cancerphas iimerkel cell carcinomaphas iianal cancerphas arg solid tumor phase i/ii novel mechan target myeloid cell develop expect focu combo gitr solid tumor phase i/ii await proof-of-concept tumor phase i/ii await proof-of-concept axl/mer solid tumor phase i/ii dose-escalationpotenti immune-direct target therapi agent i/ii await proof-of-concept i/ii await proof-of-concept dataatop dermatitisphas vitiligophas iiphas suppurativa phase tacitinib colitisphas iipemphigu vulgarisphas iiautoimmun hemolyt anemiaphas iisjogren syndromephas iirheumatoid arthritisapprov europ japan dose approv doseatop dermatitisphas psoriat arthritisphas phase prepar lilli system lupu erythematosusphas sever alopecia areataphas ii/capmatinib licens novarti non-smal cell lung cancer liver cancernda expect yearnda nsclc patient exon skip mutat sourc compani reportsexhibit corporationpipelin progressruxolitinib topic ruxolitinib target therapiescanc immun therapiespartn william blair
drugpeak salesstag developmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair marketedapprov nov marketedapprov juli eu marketedapprov februari tier phase phase tier present valu addit william blair estimatessum-of-part fair valu exhibit corporationfair valuenet year-end import disclosur
